and thank everyone, for morning, Avanos. Good Dave. interest Thanks, you your in
a to year, delivered at the things by responding position. solid the products, needs remained life-saving their the ensuring the three the successfully to our and in their on supply succeed I'm Throughout the maintaining As meet to patients to priorities: matter and pandemic responded forefront, I getting that commitment reflect by our presented resilient of on our financial as to and to families’ respiratory We our back dedication safe, keeping team's execution, health the sufficient and inspired the our strong XXXX, challenges of challenges attitude employees continued customers. we of pandemic.
presented of we managing our each long-term top was meaningful challenges And proud priorities. of that strategy progress we the equally While on these by against remained pandemic our and I'm achieving delivered XXXX focused the priorities. mind,
The helped generated top first growth priority the which to our was franchise component CORPAK Accelerating launched another Within growth NeoMed key we internationally, by urgent we needs growth customers. year our Health closed demands. to by Care across increasing international aided partially achieved in our growth regions double-digit Also our production our Digestive In strategy, meet pandemic-related the to standard-of-care double-digit Chronic clinically suction growth capacity Respiratory our is line CORTRAK across our opportunity of drive quickly franchises. maximized catheters of portfolio. Health proven This contribute of portfolio sales we double-digit strategy. growth. in the
Leiters benefit. and to sales promote evaluate partnerships customers. force encouraged medical distribution postponement procedures the by evidence marketing affected and significant the At of its and the treatment of journals, solid despite sales double-digit to connections acid partnerships entered hyaluronic end capabilities of the through a to ON-Q of selling through respect continue growth we and our elective servicing potential we long-term year, this Management of with initiatives the pandemic. expand ON-Q range franchise of franchise, our stages early we While the Pain and during strengthened implemented of clinical the overall of saw osteoarthritic growth our superiority pain. these organizations start therapies, With their with due a several lower knee pain several COOLIEF medical and the advanced We for the pandemic. including we sales had I'm to clinical management to published the the demonstrating in of in to other growth articles using customers COOLIEF benefits will
our The priority was of recent acquisitions. the integration second
global final The we cash capital IT in complete the enabled forward. our maintain spending from improve half priority to that rebuild synergies a in XXXX to leveraged carry response integration us the position, home, rapid was was working generation milestone system to While the the cash disciplined of capital our progression. meaningful as of and to generate significant back that impacted resulted our pandemic costs, free while scheduled. flow, we working of each This will acquisition reduce
us on built last positions the summary, operations. three opportunities. from we we momentum, to environment quarters, In well positive quarter-over-quarter growth generated deliver future Over difficult cash and executed well which a in
In our addition a DE&I of to the we coming our Together on believe these and can thing I employees' we employees right systemic that from do, both an together kind issues understand up right appreciated advance and if efforts, and organization we're so we're of from have to better stand we regions is inequality, we'll racial in to where organization standpoint. want assembling to for to everyone work diversity, initiative heard. the priorities, these of and what regarding Stand it's we began departments the That's initiatives. the levels, where all of valued, social gender business comprised our We're identify various and council, and and doing the We inclusion midst short. perspectives equity
quarter. results. compared $X.XX per earned quarter earnings the with disciplined were We adjusted of totaled cost Sales prior our to control positively while X% the year Now to solid we share. Earnings a fourth diluted million by our measures. $XXX impacted year, turning lower ended
Digestive against Respiratory CORPAK Care Management though overall double-digit NeoMed, growth even In to a limited, as business, in we continued by Health. in quarter growth suppressed. a elective was for the our We cycled year remain and prior see strong saw comparison. Chronic In procedures Health we strong demand Pain driven
into dynamic COVID-related start sequentially Although, in spiked procedures. the continued, the some as grew the quarter, resulting suspension December, has slow to year. began additional in elective sales in for of regions, of they hospitalizations This
Management. procedural solid expect its to its growth, below we an likely accelerate Pain, In remain enhanced but our for care throughout Pain we by full across announced to build sequential radio unfolds, will most ambulatory caused reimbursement volume in year the CMS near-term performed potential, Despite the the year. As the to foundation of surgical believe improvement, see pandemic, on procedures, rule for setting. continue knee frequency Interventional headwinds
that presented, is of XX-month While function years operational two Pain procedure. private our advantages development, COOLIEF see as These a Acute clinical return to not catalyst, trial, Pain following drive multi-centered patients that Interventional benefits Also, improved to, over business and public can an and lasting pain Annual at on randomized immediate catalysts and improvements we we in a that single the will Management and Management growth XX-month this the educating identified, our indicated and through our data, efficiencies Pain up meeting. positive continue economic the from large combined will both and COOLIEF. sales recently coming teams payers, both, newly quarters.
our Looking ahead, we of well positioned four creation. strategies advance across are to value areas
the generation. that growth, drive years, yet our margin foundation in necessary, we've expansion, cash significant, leverage flow made XXXX help sustainable business growth. to beyond, several past investments we'll us top for and In infrastructure line Over our future and to strengthen
we'll strengthen profile. First, further sales our growth
as Health to growth, increasing Health to the In along We we'll Management, clinical further, the COOLIEF. our enteral for and further of Respiratory market-leading NeoMed portfolios, neonatal, further reimbursement will with continue our feeding, improve feeding enhance executing Pain building to continue standard-of-care to adoption by establish strategy Digestive address leverage nasogastric CORTRAK needs. our for to evidence,
drive to leveraging selling therapy relationships ON-Q, sales. And raise For adoption. we're
in gross our expand for Respiratory and a Pain shift we'll Second, Gross Management be operating will improvement higher-margin subside. margin in mix, Health partially to products And return product XXXX as driven products growth. by margins. demand
manufacturing cost Additionally, at efficiencies, our we'll continue locations. and to drive savings
divestiture, margin portion expect year to cost we the while implemented, the part cost the in of in expansion pandemic. to a in savings operating our for program we making As a permanent XXXX, savings response savings, as drive of our identified we of final S&IP
XXXX to our we team corporate as Additionally, Also, post-COVID and customer streamlined leadership our as senior drive franchise environment. efficiencies strengthen that restructuring my for implemented a addressed a requirements, we further relationships. functions, well program workspace other and recently
our and Finally, as recent them. high from integrated mentioned synergies earlier, I we've real acquisitions with
of at advance enhancing we culture, by creation, approach looking embedding through needs. into processes this the business, with of efficiencies our value goal we're customers' the lens As our meeting while all effectively more
is that as in higher I tax value pathway creation Act. XXXX, expected cash the provisions to than available flow. generate the more receiving cost an refunds, flow, well the million US to consistent million In primarily disciplined driven we Our from derived free of through mentioned $XXX third savings CARES earnings and just repeatable $XX anticipate generating as cash by
for deployment fourth Our disciplined capital pathway M&A. is
balancing towards We a of executing have a growth valuation. with eye record value-enhancing disciplined and acquisitions, track solid
footprint, team leverage generate tuck-in continues opportunities and our to identify that existing synergies enhance potential and line top would Our evaluate growth profile. our
margin the of generate portfolio focus our can execution XXXX in strong our optimistic prospect bolstering and ensuring am in team beyond. strong. a expansion and robust on return This, deliver and While along In our we I our so XXXX, do manner, we on we'll gives with only growth a capital. disciplined summary, in about portfolio remain me market-leading confidence
Now, I'll turn call over the Michael. to
